Aquestive Therapeutics (AQST) Research & Development (2017 - 2026)

Aquestive Therapeutics' Research & Development history runs 10 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Research & Development fell 21.58% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $16.0 million (down 18.64% YoY), while the FY2025 annual figure was $17.2 million, down 15.23% from the prior year.
• Research & Development was $4.2 million for Q1 2026 at Aquestive Therapeutics, up from $3.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $5.9 million in Q1 2024 to a low of $2.9 million in Q4 2023.
• Historically, Research & Development has averaged $4.3 million across 5 years, with a median of $4.2 million in 2026.
• The sharpest annual moves came in 2024 and 2025: Research & Development jumped 70.26% in 2024, then sank 35.0% in 2025.
• A 5-year view of Research & Development shows it stood at $4.3 million in 2022, then sank by 32.49% to $2.9 million in 2023, then soared by 70.26% to $4.9 million in 2024, then tumbled by 35.0% to $3.2 million in 2025, then soared by 31.54% to $4.2 million in 2026.
• The last three Research & Development figures came in at $4.2 million (Q1 2026), $3.2 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.